30 mcg-0.15 mg; 20 mcg-100 mcg; 20 mcg-90 mcg; triphasic; biphasic extended cycle; quadriphasic extended cycle; low dose biphasic extended cycle; 0.05 mg-0.25 mg; extended cycle 30 mcg-0.15 mg; with iron 20 mcg-100 mcg
Pregnancy, undiagnosed vag bleeding, severe arterial disease (or family history of atherogenic lipid profile); liver adenoma; porphyria; after evacuation of hydatidiform mole; history of breast cancer; hepatic impairment; thrombophloebitis or thromboembolic disorders; breast carcinoma except in selected patients being treated for metastatic disease; oestrogen-dependent tumour; smoking 40 cigarettes daily; >50 yr; diabetes complications present; BMI >39 kg/m2; migraine w/ typical focal aura, lasting >72 hr despite treatment or migraine treated w/ ergot derivatives; BP >160 mmHg systolic & 100 mmHg diastolic; transient ischaemic attacks w/o headaches; SLE; gallstones; history of haemolytic uraemic syndrome. pruritis during pregnancy; cholestatic jaundice; chorea or deterioration of otosclerosis pemphigoid; breast feeding during 1st 6 mth after delivery. Sex-steroid dependent cancer; past ectopic pregnancy; malabsorption syndromes; functional ovarian cysts; active liver disease, recurrent cholestatic jaundice, history of jaundice in pregnancy; history of CV or renal impairment; DM; asthma; epilepsy; migraine; depression; lactation; conditions exacerbated by fluid retention; hypercalcaemia; CV & gall bladder diseases; lipid effects; familial defects of lipoprotein metabolism; patients at risk of venous thromboembolism, breast cancer, preexisting uterine leiomyomata & benign hepatic adenoma; family history of arterial disease in 1st degree relative <45 yr; BP> systolic 140 mmHg & diastolic 90 mmHg; >35 yr; BMI 30-39 kg/m2; migraine w/o focal aura, controlled w/ 5HT1; GI upset (vomiting & diarrhoea), missed pills & interaction w/ other drugs may require additional contraceptive precautions. Should be taken at same time each day.
Menstrual irregularities; headache, dizziness; breast discomfort; gynaecomastia; depression; disturbance of appetite; wt changes; fluid retention; oedema; changes in libido; hair loss or hirsutism; GI disturbances (nausea & vomiting); genitourinary changes; haematologic disorders; endocrine & metabolic disorders; cholestatic jaundice; local skin reactions; chorea; contact lens intolerance; steeping of corneal curvature; pulmonary thromboembolism; carbohydrate and/or glucose intolerance; depression; chloasma; BP increase, liver impairment; reduced menstrual loss, ?spotting’ in early cycles, absence of withdrawal bleeding; rarely photosensitivity; increased risk in breast cancer; elevation of plasma bound iodine, cortisol & thyroid binding, erythrocyte sedimentation may be accelerated; increases in plasma copper, Fe & alkaline phosphatase; may affect serum TG & lipoprotein levels; retinal vascular thrombosis. Hepatic tumours; increased risk of thromboembolism.
Use is contraindicated during pregnancy. Breastfeeding is not recommended during use of this drug.
.png&w=384&q=75)